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Abstract
There is considerable interest in the gynecologic cancer community for the development of
biomarkers that will be of utility in routine management of women with advanced ovarian cancer.
However, at the present time, there remains limited evidence for the usefulness of any such test
other than the serum cancer antigen (CA)-125 level, employed to monitor the course of disease in
response to treatment or during periods of observation.
Introduction and context
Despite the high objective response rate (>60–70%) of
epithelial ovarian cancer to platinum-based cytotoxic
chemotherapy, the majority of patients will ultimately
experience progression of the disease process. Further-
more, as many as one-third of patients either will fail to
experience any meaningful response to a frontline
platinum-based regimen (disease progression or ‘stable
disease’ as the best response) or will have very early
documentation of progression (for example, during or
within several months following the completion of
primary therapy).
As a result, there has been considerable interest within
the gynecologic oncology research community for the
development of in vitro tumor assay systems or serum
biomarkers that may be reliably used to (a) provide an
accurate early indication of prognosis (prognostic test) or
(b) to predict the effectiveness of an alternative manage-
ment strategy in a patient whose disease has been
documented to have progressed or where the test
suggests an unfavorable outcome with the current
strategy (predictive test). Unfortunately, despite consid-
erable efforts by many investigators to establish reliable
predictive tests, very few formally validated strategies (for
example, estrogen receptor in breast cancer) currently
exist in the oncology arena, and it would be most
appropriate to firmly state that, to date, no such test
satisfies this criterion in the area of epithelial ovarian
cancer.
Recent advances
Conversely, a number of recent studies in ovarian cancer
have reported on the ability of a variety of strategies to
assist in the prognostic classification of patients with this
malignancy. These approaches have included determin-
ing the relationship between the subtypes of infiltrating
T-cells and other presumed immunoregulatory cells
within the tumor [1,2], specific (but quite complex)
patterns of serum biomarkers observed prior to the
administration of chemotherapy [3,4], the unique
methylation status of DNA obtained from the tumor
[5], the presence (or absence) of a particular tumor-
associated glycoprotein [6], specific pre-treatment cancer
gene expression [7,8], and mRNA profiles [9].
For a number of the newly reported prognostic factors,
validation studies on a completely independent data set,
undertaken by investigators not involved in the initial
analysis, have yet to be performed (or at least have yet to
be reported in the peer-reviewed oncology literature).
Such efforts must be considered an absolute requirement
before any new prognostic (or predictive) test can be
seriously discussed for inclusion as a component within
the routine management of ovarian (or any other type
of) cancer.
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similar to those noted above for the previously demon-
strated prognostic utility of the serum cancer antigen
(CA)-125 level, in a preliminary report of a phase
3 frontline ovarian cancer chemotherapy trial, a group of
investigators proposed a rather provocative and novel
use of this tumor marker [10]. The study compared an
investigative approach (cisplatin plus topotecan fol-
lowed by carboplatin plus paclitaxel) with a ‘standard’
carboplatin plus paclitaxel regimen, and surprisingly
revealed a lower objective response rate and shorter
progression-free survival associated with delivery of this
experimental program.
One prospectively defined component of this trial was
the collection of the serum CA-125 antigen level prior to
the administration of the third cycle of chemotherapy.
The study revealed a statistically significant (P = 0.006)
lower percentage of patients in the experimental arm
(57.5%) whose serum antigen level had normalized by
this point in the course of their illness, compared with
the ‘standard regimen’ (66.3%). Of relevance to the
previous discussion of a predictive versus a prognostic
test, the biological marker did not predict which patients
would respond to a particular therapy but simply (and
importantly) demonstrated that treatment on the control
arm was associated with a superior prognosis.
Implications for clinical practice
In the opinion of this commentator, it is not unreason-
able to inquire whether there is an actual need for any
additional prognostic markers in advanced epithelial
ovarian cancer beyond those currently routinely used
(for example, cancer stage, tumor grade, optimal/
suboptimal surgical cytoreduction, patient age and
existing serious co-morbidity, and in the setting of
recurrent/persistent disease, prior therapy and treatment/
platinum-free interval).
Unless the knowledge gained through the completion of
any of these tests is of substantially greater utility than
tumor stage and grade (and so on) or the test can
reproducibly predict a superior outcome if an alternative
regimen (for example, ‘drug A’ plus ‘drug B’ rather than
carboplatin plus paclitaxel) is employed based on the
particular biological characteristics of the tumor, then
what is the actual value associated with obtaining the
test, outside the setting of an investigative trial? It will be
important for investigators exploring the development of
new prognostic markers in epithelial ovarian cancer to
provide a response to this question.
Although the provocative results of the CA-125 study
described above will need to be confirmed (validated) by
investigators with independent data from separate trials,
it may be possible to employ this objective, cost-
effective, and easily obtained ‘marker of prognosis’ to
decide at a relatively early point in time whether a
particular study should be closed for inferiority of one
study arm or potential ‘futility’ (assuming no difference
between the treatment regimens). Such an outcome may
substantially shorten the duration of frontline ovarian
cancer treatment trials and reduce the number of patients
required to definitively document the effectiveness of a
novel approach to management of the malignancy.
Furthermore, strategies destined to be proven to be
ineffective could be discarded, thereby minimizing the
potential harm to research subjects who would otherwise
have been treated with this investigative program.
It is also important to note the potential relevance of a
focus on separately analyzing specific subtypes of
ovarian cancer in future research efforts in this arena.
For example, existing data demonstrate striking differ-
ences in the clinical behavior of mucinous and clear cell
tumors of the ovary compared with that of other
epithelial histologies [11]. In this regard, it may be
possible to develop biomarkers that are highly clinically
relevant for a particular subtype.
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